Metformin glycinate

DRUG5 trials

Sponsors

Laboratorios Silanes S.A. de C.V.

Conditions

Metabolic SyndromeSevere Acute Respiratory Syndrome Coronavirus 2Type 2 Diabetes

Phase 2

Efficacy Study of Metformin Glycinate on Postprandial Lipemia

Laboratorios Silanes S.A. de C.V.Type 2 Diabetes

Start: 2015-10-31End: 2020-08-31Target: 72Updated: 2018-01-30

Metformin Glycinate in Patients With MS or DM2 , Hospitalized With COVID-19 and SARS Secondary to SARS-CoV-2

WithdrawnNCT04626089

Laboratorios Silanes S.A. de C.V.Metabolic Syndrome, Severe Acute Respiratory Syndrome Coronavirus 2, Type 2 Diabetes

Start: 2021-02-28End: 2021-02-28Updated: 2021-04-08

Metformin Glycinate, Treatment of Patients With COVID-19 and Severe Acute Respiratory Syndrome Secondary to SARS-CoV-2.

CompletedNCT04625985

Laboratorios Silanes S.A. de C.V.Severe Acute Respiratory Syndrome Coronavirus 2

Start: 2020-07-14End: 2021-03-18Updated: 2021-04-08

Phase 3

Metformin Glycinate on Metabolic Control and Inflammatory Mediators in Type 2 Diabetes

CompletedNCT01386671

Laboratorios Silanes S.A. de C.V.Type 2 Diabetes

Start: 2014-06-30End: 2018-01-31Updated: 2018-01-30

Efficacy and Safety of Metformin Glycinate Compared to Metformin Hydrochloride on the Progression of Type 2 Diabetes

SuspendedNCT04943692

Laboratorios Silanes S.A. de C.V.Type 2 Diabetes

Start: 2021-08-31End: 2021-08-31Target: 500Updated: 2021-06-29

Related Papers

146-LB: Efficacy and Safety of Metformin Glycinate vs. Metformin Hydrochloride in Metabolic Control and Inflammatory Mediators in Type 2 Diabetes Mellitus Patients (T2DM)

Diabetes2019-06-011 citations